All In MedTech

FDA Clearance Tracker · P240021

Atellica IM Total PSA II (tPSAII)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 3, 2025

Approved

Time to decision

531 days

Received Jun 20, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240021
Device name
Atellica IM Total PSA II (tPSAII)
Applicant location
Tarrytown, NY
Received
Jun 20, 2024
Decided
Dec 3, 2025
Decision
Approved
Supplements
1 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica IM Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MTF. The earliest in FDA's data is P850048, decided Feb 25, 1986.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Siemens Healthcare Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.